Share on StockTwits
 

Boston Scientific Corp. (NYSE:BSX) Director Kristina M. Johnson sold 18,000 shares of the stock on the open market in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $13.01, for a total transaction of $234,180.00. Following the sale, the director now directly owns 3,124 shares of the company’s stock, valued at approximately $40,643. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Boston Scientific Corp. (NYSE:BSX) traded up 2.07% on Friday, hitting $13.30. The stock had a trading volume of 14,856,356 shares. Boston Scientific Corp. has a 1-year low of $7.07 and a 1-year high of $14.08. The stock has a 50-day moving average of $12.97 and a 200-day moving average of $11.. The company’s market cap is $17.678 billion.

Boston Scientific Corp. (NYSE:BSX) last released its earnings data on Tuesday, February 4th. The company reported $0.21 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.13 by $0.08. The company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter in the prior year, the company posted $0.18 earnings per share. The company’s quarterly revenue was up .9% on a year-over-year basis. On average, analysts predict that Boston Scientific Corp. will post $0.50 earnings per share for the current fiscal year.

A number of research firms have recently commented on BSX. Analysts at Jefferies Group raised their price target on shares of Boston Scientific Corp. from $12.00 to $13.00 in a research note on Wednesday, February 5th. Separately, analysts at Cowen and Company raised their price target on shares of Boston Scientific Corp. from $14.00 to $15.00 in a research note on Friday, January 31st. Finally, analysts at Piper Jaffray upgraded shares of Boston Scientific Corp. from a “neutral” rating to an “overweight” rating in a research note on Tuesday, January 21st. They now have a $18.00 price target on the stock, up previously from $12.00. Nine research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Boston Scientific Corp. presently has an average rating of “Buy” and a consensus price target of $12.54.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.